Women and Alcoholism: An Individual Patient Data (IPD) Meta-Analysis of Outcome Predictors Based on 935 Female Patients in 16 Acamprosate Clinical Trials

Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A meta-analysis was carried out to compare acamprosate with placebo on women patients on TA and CA. 21 randomized, placebo-controlled trials (RCTs) that fulfilled predetermined selection criteria were identified. Primary outcome measures were percent days of TA (defined as zero drinks during the treatment interval) and CA (defined as <5 standard drinks/day during the treatment interval). TA and CA rates were also significantly higher with patients treated with acamprosate vs. placebo (43.5% vs. 23.2%; RR, 0.64; P<.001) with an NNT=5.8. Acamprosate can provide a significant benefit in women by reducing alcohol consumption during relapse.Meta analyse de 21 études randomisées en double aveugle dans l'etude de l'efficacité d'acamprosate dans le sevrage alcoolique. Les criteres de jugements ont été l'abstinence totale TA et l'abstinence contrôlée CA. les ratios CA et TA rates furent observés significtaivement supérieurs dans le groupe acamprosate(43.5% vs. 23.2%; RR, 0.64; P<.001) with an NNT=5.8. Acamprosate s'accompagne donc d'un bénéfice significatif chez ls patients de sexe féminin dans la reduction de la consommation alcoolique